Search clinical trials for: ADX-629

Total 3251 results

Aldeyra Therapeutics, Inc.

Withdrawn

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Nephrotic Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Aldeyra Therapeutics, Inc.

Completed

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Atopic Asthma

Canada
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Chronic Cough

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Covid19

United States
University of Nebraska

Recruiting

ADX-629 Therapy for Sjogren-Larsson Syndrome

Sjogren-Larsson Syndrome

United States
Aldeyra Therapeutics, Inc.

Recruiting

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Atopic Dermatitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

Ethanol Intoxication

United States
Seoul National University Hospital
NewGenPharm Inc.

Completed

Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer (Theragene)

Pancreatic Cancer

Korea, Republic of
YourChoice Therapeutics, Inc.

Recruiting

First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males

Male Contraception

United Kingdom
Hutchison Medipharma Limited

Completed

A Study of HMPL-689 in Healthy Volunteers

Healthy Volunteers

Australia
Henry Ford Health System

Recruiting

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

Glioma | Glioblastoma | Astrocytoma | Malignant Glioma of Brain | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | GBM | Malignant Astrocytoma

United States
Forendo Pharma Ltd
Richmond Pharmacology Limited

Completed

A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations

Relative Bioavailability

United Kingdom
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes

Recurrent Genital Herpes
Alkermes, Inc.
QPS Netherlands B.V.

Completed

Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects

Healthy

Netherlands
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditions

United States
Sorrento Therapeutics, Inc.

Recruiting

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Light Chain (AL) Amyloidosis

United States
Hutchmed

Active, not recruiting

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

Lymphoma

Spain, United States, France, Italy, Finland, Poland
Calithera Biosciences, Inc

Terminated

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Canada, France, United Kingdom
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Advanced Solid Tumor and Lymphoma Malignancies

United States, Spain, Italy, United Kingdom
Anthera Pharmaceuticals

Completed

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Systemic Lupus Erythematosus

United States, Argentina, Brazil, Chile, Colombia, Hong Kong, India, Mexico, Peru, Philippines, Taiwan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating LXR-623 in Healthy Japanese Adults

Healthy

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating LXR-623 in Healthy Subjects

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029

Healthy
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Hutchison Medipharma Limited

Completed

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

Lymphomas

China
Concert Pharmaceuticals

Completed

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

Healthy

United States
Avelas Biosciences, Inc.

Completed

Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery

Breast Cancer

United States
Medivir

Completed

Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents

Herpes Labialis
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating MYO-029 in Adult Muscular Dystrophy

Becker Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy | Limb-Girdle Muscular Dystrophy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluation LXR-623 in Healthy Adults

Healthy Subjects
Calithera Biosciences, Inc

Withdrawn

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Advanced Solid Neoplasms | Lymphoma Neoplasms
Benjamin Movsas, M.D.

Withdrawn

Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer (NSCLC)

Non-small Cell Lung Cancer Stage I

United States
Henry Ford Health System

Completed

Randomized Trial of Suicide Gene Therapy and Prostate Cancer (ReCAP)

Prostate Cancer

United States
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Churg-Strauss Syndrome | Eosinophilic Granulomatosis With Polyangiitis

United States, Japan
Sirtsei Pharmaceuticals, Inc.

Completed

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

Schizophrenia

United States
EVIVE Biotechnology

Completed

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
Forendo Pharma Ltd
Richmond Pharmacology Limited

Completed

A Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics and Pharmacodynamics of FOR-6219

Endometriosis

United Kingdom
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Henry Ford Health System

Terminated

Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
M.D. Anderson Cancer Center

Withdrawn

STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Acute Myeloid Leukemia (AML) | Refractory T Acute Lymphoblastic Leukemia

United States
Q32 Bio Inc.
Innovaderm Research Inc.

Recruiting

Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Alopecia Areata

United States
Jazz Pharmaceuticals

Completed

A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

Narcolepsy

United States
Jazz Pharmaceuticals

Completed

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Narcolepsy

United States
Nested Therapeutics, Inc

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)

Glioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene Mutation

Australia
Children's Hospital Medical Center, Cincinnati
National Institutes of Health (NIH)

Recruiting

Improving Outcomes in Pediatric Obstructive Sleep Apnea With Computational Fluid Dynamics (OSA-MRI)

Obstructive Sleep Apnea

United States
Metro International Biotech, LLC
Children's Hospital of Philadelphia

Completed

NAD+ Precursor Supplementation in Friedreich's Ataxia

Friedreich Ataxia

United States
Calithera Biosciences, Inc

Withdrawn

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Lymphoma, Malignant | Advanced Solid Neoplasms

United States
Calithera Biosciences, Inc

Terminated

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin | Lymphoma, Follicular, Marginal Zone

Korea, Republic of, Japan
Calithera Biosciences, Inc

Terminated

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada

Search clinical trials for: ADX-629

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations